Publications by authors named "Jian-hai Guo"
Article Synopsis
- * HAIC using oxaliplatin, fluorouracil, and leucovorin (referred to as HAIC-FOLFOX) has shown better survival rates than standard first-line treatments, but inconsistencies in the HAIC procedure have led to challenges in its safe application.
- * An expert consensus conference held in March 2023 in Guangzhou, China resulted in 22 recommendations that cover the candidate assessment, technical details, outcomes, complications, and management strategies related to HA
Article Synopsis
- - The study aimed to compare the effectiveness and safety of two chemotherapy treatments—HAI of oxaliplatin plus raltitrexed (TOMOX) and HAI of oxaliplatin plus 5-fluorouracil (FOLFOX)—for patients with unresectable colorectal cancer liver metastases (CRCLM).
- - A total of 113 patients were randomly assigned to receive either TOMOX or FOLFOX, with primary endpoints focusing on progression-free survival (PFS) and objective response rate (ORR), while secondary endpoints included overall survival (OS) and adverse events.
- - Results showed no significant difference between the two treatments in terms of PFS (5.8 months for
Article Synopsis
- The study examined the effectiveness and safety of combining hepatic artery infusion chemotherapy (HAIC) with anti-PD-1 immunotherapy and tyrosine kinase inhibitors (TKIs) in treating advanced hepatocellular carcinoma (HCC).
- A total of 27 patients were analyzed, with a median follow-up of 12.9 months, showing a median progression-free survival of 10.6 months, an objective response rate of 63.0%, and a disease control rate of 92.6%.
- No patients experienced treatment-related deaths, indicating that the combined therapy was both effective and safe for advanced HCC.
Article Synopsis
- A clinical trial assessed the effectiveness and safety of I-labeled metuximab in combination with transcatheter arterial chemoembolization (TACE) for treating patients with unresectable hepatocellular carcinoma.
- Results showed that patients receiving TACE along with I-metuximab experienced a median time to tumor recurrence of 6 months compared to 3 months for those receiving TACE alone.
- Additionally, the combined treatment led to a median overall survival of 28 months versus 19 months for TACE alone, demonstrating better outcomes and good patient tolerance for the new treatment.
Article Synopsis
- Patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT) generally have poor survival rates, but this study explored how combining conventional transarterial chemoembolization (cTACE) with hepatic arterial infusion chemotherapy (HAIC) affects outcomes.
- In a retrospective evaluation of 155 patients, those receiving the combination treatment (cTACE-HAIC) showed significantly longer overall survival (9 months) and progression-free survival (6 months) compared to those who received cTACE alone (5 months and 2 months, respectively).
- The study concluded that cTACE-HAIC is associated with better survival outcomes without increasing severe treatment-related side effects compared to cTACE alone.
Article Synopsis
- TACE and HAIC are treatments for advanced hepatocellular carcinoma (HCC) that show local effectiveness, and S-1 is an oral chemotherapy that works against advanced HCC.
- This study aimed to evaluate the safety and effectiveness of combining TACE and HAIC with or without S-1 in patients with advanced HCC.
- Results showed no significant improvement in tumor response rates or survival outcomes when S-1 was added, and both treatment approaches had similar safety profiles.
Article Synopsis
- The study examines the effectiveness and safety of combining sorafenib with hepatic arterial infusion chemotherapy (HAIC) after transarterial chemoembolization (TACE) for patients with intermediate and advanced hepatocellular carcinoma (HCC).
- Conducted as a phase II trial, sixty-six participants were treated with sorafenib followed by intra-arterial administration of chemotherapy agents, with safety and progression-free survival as key outcomes.
- Results showed an objective response rate of 42.4% and a disease control rate of 87.9%, though some patients experienced significant toxicity, including grade 3-4 side effects like thrombocytopenia.
Article Synopsis
- - The study aims to compare the survival outcomes of patients with right-sided primary (RSP) tumors versus left-sided primary (LSP) tumors undergoing hepatic arterial infusion chemotherapy (HAIC) for metastatic colorectal cancer.
- - A total of 168 patients were analyzed, revealing similar response rates and disease control rates for both tumor sides; median overall survival was 16.3 months for LSP patients and 9.3 months for RSP patients.
- - The results show no significant survival difference between LSP and RSP patients post-treatment, indicating a need for further research to confirm these observations.
Article Synopsis
- The study aimed to evaluate the effectiveness of trefoil factor family 3 (TFF3) as a biomarker for the early detection of colorectal cancer (CC).
- Researchers tested serum levels of TFF3 and carcino-embryonic antigen (CEA) in 527 participants, including healthy individuals and patients with colorectal adenoma and cancer.
- The findings indicated that TFF3 levels were significantly higher in CC patients compared to controls and suggested that a combined model of TFF3 and CEA could improve diagnostic accuracy significantly over using CEA alone.
Hepatic artery infusion with raltitrexed or 5-fluorouracil for colorectal cancer liver metastasis.
World J Gastroenterol
February 2017
Article Synopsis
- The study aimed to assess the effectiveness and safety of two types of chemotherapy (raltitrexed versus 5-fluorouracil) delivered through hepatic artery infusion for treating liver metastases from colorectal cancer in patients who didn't respond to previous treatments.
- A total of 42 patients were analyzed, with 24 receiving 5-fluorouracil and 18 receiving raltitrexed; results indicated no significant survival difference between the two treatment groups, with median survival times of 20.6 months for raltitrexed and 15.4 months for 5-fluorouracil after starting HAIC.
- Side effects varied, with more cases of leuk
Article Synopsis
- The study aimed to compare the effectiveness and safety of chemoembolization alone versus chemoembolization combined with hepatic arterial infusion chemotherapy (HAIC) using oxaliplatin, 5-fluorouracil, and folinic acid for patients with inoperable hepatocellular carcinoma (HCC).
- A total of 84 inoperable HCC patients participated, with 39 receiving only chemoembolization and 45 receiving the combined treatment; they evaluated progression-free survival, objective response rates, disease control rates, and adverse effects.
- Results indicated that the combination treatment showed improved objective response rates and median progression-free survival compared to chemoembolization alone, though it also led to increased pain levels, but for advanced-stage
Article Synopsis
- This study assesses the effectiveness and safety of combining regional chemotherapy via the hepatic artery with transarterial embolization in advanced gastric cancer patients who have liver metastases, particularly after unsuccessful prior treatments.
- A total of 22 patients received a median of 7 treatments, showing a median time-to-progression of about 6 months and a median overall survival of nearly 19 months following the diagnosis of liver metastasis.
- The combination therapy led to a reduced overall chemotherapy dosage, fewer side effects, and improved quality of life for the patients, suggesting its potential as a salvage treatment option.
[Angiographic findings and interventional therapy for post-pancreaticoduodenectomy hemorrhage].
Zhonghua Yi Xue Za Zhi
January 2013
Article Synopsis
- The study analyzed angiographic findings and the effectiveness of interventional therapy in 29 patients who experienced bleeding after pancreaticoduodenectomy from August 2009 to June 2012.
- The results indicated that bleeding occurred between 8 hours to 72 days post-surgery, with a high success rate of 93.94% and a hemostatic rate of 90%, although there were 3 patient deaths.
- The researchers concluded that embolization therapy is a safe and effective first-line treatment for post-pancreaticoduodenectomy hemorrhage.
Article Synopsis
- The study aimed to assess serum vascular endothelial growth factor (VEGF) levels in patients with unresectable hepatocellular carcinoma (HCC) and their correlation with various clinical and pathological characteristics, as well as their potential as a predictive marker for HCC prognosis during transarterial chemoembolization (TACE).
- Serum VEGF levels were measured in 60 HCC patients undergoing TACE and compared to 12 healthy controls, revealing significantly higher VEGF levels in HCC patients and a correlation with platelet counts.
- The findings indicated that patients with serum VEGF levels above 285 pg/ml had a worse overall survival rate, establishing high serum VEGF as a significant prognostic factor for HCC after TACE.
[Profiles of type 1 and type 2 T cells in chronic idiopathic thrombocytopenic purpura].
Zhonghua Yi Xue Za Zhi
March 2006
Article Synopsis
- The study aimed to examine the profiles of type 1 and type 2 T cells in patients with chronic idiopathic thrombocytopenic purpura (ITP), comparing their immune responses to healthy individuals.
- Blood samples were taken from 30 chronic ITP patients and 20 healthy controls, then analyzed for various T cell populations and cytokine levels using flow cytometry and real-time PCR methods.
- Results showed significantly higher Th1/Th2 and Tc1/Tc2 ratios in active ITP patients compared to those in remission and the control group, indicating a distinct immune profile associated with the disease's active phase.